Insulet Corporation $PODD Shares Acquired by Westfield Capital Management Co. LP

Westfield Capital Management Co. LP boosted its stake in shares of Insulet Corporation (NASDAQ:PODD) by 91.9% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 386,468 shares of the medical instruments supplier’s stock after purchasing an additional 185,081 shares during the quarter. Westfield Capital Management Co. LP owned approximately 0.55% of Insulet worth $109,850,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Larson Financial Group LLC boosted its position in Insulet by 114.6% during the 4th quarter. Larson Financial Group LLC now owns 88 shares of the medical instruments supplier’s stock worth $25,000 after acquiring an additional 47 shares during the period. Elyxium Wealth LLC acquired a new position in Insulet during the 4th quarter worth $28,000. Fideuram Asset Management Ireland dac acquired a new position in Insulet during the 4th quarter worth $41,000. Measured Wealth Private Client Group LLC acquired a new position in Insulet during the 3rd quarter worth $49,000. Finally, Osterweis Capital Management Inc. acquired a new position in Insulet during the 2nd quarter worth $51,000.

Analysts Set New Price Targets

A number of research analysts have issued reports on the company. BTIG Research reduced their price target on Insulet from $260.00 to $235.00 and set a “buy” rating for the company in a research report on Tuesday, May 26th. JPMorgan Chase & Co. reduced their price target on Insulet from $340.00 to $275.00 and set an “overweight” rating for the company in a research report on Thursday, May 7th. Benchmark reiterated a “buy” rating on shares of Insulet in a research report on Wednesday, May 27th. Wells Fargo & Company reduced their price target on Insulet from $360.00 to $255.00 and set an “overweight” rating for the company in a research report on Wednesday, May 6th. Finally, Sanford C. Bernstein reduced their price target on Insulet from $330.00 to $200.00 and set an “outperform” rating for the company in a research report on Thursday, May 7th. Twenty-one equities research analysts have rated the stock with a Buy rating, five have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $252.04.

Insiders Place Their Bets

In other Insulet news, Director Timothy C. Stonesifer purchased 2,790 shares of the company’s stock in a transaction that occurred on Wednesday, June 3rd. The shares were purchased at an average cost of $143.51 per share, with a total value of $400,392.90. Following the completion of the transaction, the director owned 9,041 shares of the company’s stock, valued at approximately $1,297,473.91. This represents a 44.63% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders own 0.36% of the company’s stock.

Insulet Stock Up 2.2%

Shares of Insulet stock opened at $146.41 on Friday. The stock’s fifty day moving average is $176.99 and its 200-day moving average is $239.50. The firm has a market capitalization of $10.14 billion, a PE ratio of 34.05, a price-to-earnings-growth ratio of 1.13 and a beta of 1.13. The company has a quick ratio of 1.81, a current ratio of 2.49 and a debt-to-equity ratio of 0.71. Insulet Corporation has a 12-month low of $140.63 and a 12-month high of $354.88.

Insulet (NASDAQ:PODD) last announced its earnings results on Wednesday, May 6th. The medical instruments supplier reported $1.42 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.19 by $0.23. The company had revenue of $761.70 million for the quarter, compared to analyst estimates of $729.89 million. Insulet had a return on equity of 26.87% and a net margin of 10.44%.Insulet’s revenue for the quarter was up 33.9% compared to the same quarter last year. During the same period in the previous year, the firm earned $1.02 earnings per share. Insulet has set its FY 2026 guidance at 6.210- EPS. Equities analysts anticipate that Insulet Corporation will post 6.44 earnings per share for the current year.

Insulet Profile

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.